Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02393157 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Study acronym: O-ICE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 2024 to Dec 2026
    • Study completion date: Dec 2024 to Dec 2027
    v10
  2. Primary completion date: Dec 2023 to Dec 2024
    • Start date: Feb 2015 to Aug 21, 2015
    v9
  3. Primary completion date: Dec 2022 to Dec 2023
    • Study completion date: Dec 2023 to Dec 2024
    v8
  4. Primary completion date: Dec 2020 to Dec 2022
    • Study completion date: Dec 2021 to Dec 2023
    v7
  5. Primary completion date: Dec 2019 to Dec 2020
    • Study completion date: Dec 2020 to Dec 2021
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Primary completion date: Dec 2018 to Dec 2019
    • Study completion date: Jun 2019 to Dec 2020
    v5
  2. Re-verified, no change to tracked fieldsv4
  3. Site contact updatedv3
  4. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).
Trial Details
NCT Number NCT02393157
Lead Sponsor New York Medical College
Collaborators: Roswell Park Cancer Institute
Conditions
(from sponsor)		 Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, Follicular Lymphoma, Grade III
Related terms Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov